Get the Stockscreener App
1.50
2.60%
-0.04
Sonnet Biotherapeutics Holdings Inc stock is traded at $1.50, with a volume of 17,765.
It is down -2.60% in the last 24 hours and down -13.29% over the past month.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
See More
Previous Close:
$1.54
Open:
$1.51
24h Volume:
17,765
Relative Volume:
0.02
Market Cap:
$4.72M
Revenue:
$129.20K
Net Income/Loss:
$-7.44M
P/E Ratio:
-0.134
EPS:
-11.19
Net Cash Flow:
$-8.62M
1W Performance:
+4.17%
1M Performance:
-13.29%
6M Performance:
-74.23%
1Y Performance:
-89.47%
1-Day Range:
$1.48
$1.54
1-Week Range:
$1.39
$1.57
52-Week Range:
$1.38
$18.72
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
Name
Sonnet Biotherapeutics Holdings Inc
Sector
Industry
Phone
609-375-2227
Address
100 OVERLOOK CENTER, PRINCETON, NJ
Compare SONN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
1.50 | 4.72M | 129.20K | -7.44M | -8.62M | -11.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.81 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
697.42 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
618.18 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.96 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
268.20 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Latest News
Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update - ACCESS Newswire
Sonnet BioTherapeutics Highlights Promising SON-1010 Data - TipRanks
Sonnet BioTherapeutics Presents Innovative FHAB® Platform Data at 2025 AACR:IO Conference - Nasdaq
Sonnet BioTherapeutics Presents Compilation of Data - GlobeNewswire
Can This Immunotherapy Beat Solid Tumors? Sonnet's SON-1010 Shows 48% Clinical Benefit - StockTitan
Sonnet BioTherapeutics Announces Availability of Proprietary ADC Platform for Drug Discovery Partnerships - Defense World
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
Sonnet BioTherapeutics advances novel ADC platform - Investing.com
SONN stock touches 52-week low at $1.38 amid market challenges - Investing.com India
Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships - Marketscreener.com
Sonnet BioTherapeutics Announces That Its Proprietary - GlobeNewswire
Sonnet BioTherapeutics Advances Antibody Drug Conjugate Platform - TipRanks
Sonnet BioTherapeutics advances novel ADC platform By Investing.com - Investing.com South Africa
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street - The Globe and Mail
Can This New ADC Platform Challenge Established Cancer Drugs? Preclinical Data Shows Promise - StockTitan
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference - The Manila Times
Sonnet BioTherapeutics Announces Acceptance of Poster Presentation at 2025 AACR IO Conference - Nasdaq
Revolutionary Cancer Treatment Breakthrough: Sonnet's IL-12 Protein Research Heads to AACR 2025 - StockTitan
Sonnet BioTherapeutics appoints new chief business officer - MSN
Sonnet BioTherapeutics Issues Financial Results for Q4 2024, Reports Progress in Clinical Trials and Business Development - Defense World
Sonnet Biotherapeutics Reports Increased Revenue and Strategic Developments - TipRanks
Sonnet BioTherapeutics appoints new chief business officer By Investing.com - Investing.com Nigeria
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sonnet BioTherapeutics Holdings, Inc. SEC 10-Q Report - TradingView
Sonnet BioTherapeutics reports wider Q1 net loss, CFO transition - MSN
Sonnet Biotherapeutics Appoints Stephen Mcandrew As Chief Business Officer -February 13, 2025 at 08:40 am EST - Marketscreener.com
Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer - GlobeNewswire
Strategic Move: Biologics Deal-Making Veteran Takes CBO Role at Sonnet BioTherapeutics - StockTitan
Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update - GlobeNewswire
Sonnet BioTherapeutics (SONN) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Sonnet BioTherapeutics Announces Change in Date of Annual Meeting - ACCESS Newswire
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) Secures EU Patent for FHAB Platform Technology - Defense World
Sonnet BioTherapeutics secures EU patent for FHAB technology - Pharmaceutical Technology
Sonnet BioTherapeutics Secures EU Patent for FHAB Technology - TipRanks
Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology - Marketscreener.com
Sonnet BioTherapeutics Further Expands Global Intellectual - GlobeNewswire
Game-Changing Cancer Drug Technology Gets Major EU Patent ProtectionHere's Why It Matters - StockTitan
Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum - ACCESS Newswire
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering - ACCESS Newswire
Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting - ACCESS Newswire
Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy - ACCESS Newswire
Sonnet BioTherapeutics Announces $2.25 Million Registered Direct Offering and Concurrent Private Placement - ACCESS Newswire
Sonnet BioTherapeutics begins trial combining SON-1010, trabectedin - MSN
Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - GlobeNewswire
Sonnet BioTherapeutics to expand trial of SON-1010 with trabectedin for solid tumours - Clinical Trials Arena
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - Defense World
Sonnet BioTherapeutics Expands Phase 1 Study for SON-1010 - TipRanks
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):